30 studies found for: " August 06, 2008":" September 05, 2008"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
TMC278-TiDP6-C130: Pharmacokinetics, Safety and Tolerability of TMC278 in Subjects With Mildly or Moderately Impaired Hepatic Function.
A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)
A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects
|24||Active, not recruiting||
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy
TMC278-TiDP6-C136: Effect of TMC278 on Ethinylestradiol and Norethindrone in Healthy Women.
Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen
TMC278-TiDP6-C121: Drug-drug Interaction Trial to Investigate the Potential Interaction Between TMC278 25 mg Daily and Methadone, at Steady State.
TMC114-TiDP3-C181: Study to Assess the Pharmacokinetics of Darunavir (DRV) With Different Doses of Ritonavir in Healthy Volunteers.
Study to Explore the Effect of Mefloquine in Subjects With Progressive Multifocal Leukoencephalopathy (PML)
Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma
† Indicates status has not been verified in more than two years